Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levoketoconazole Extension in Endogenous Cushing's Syndrome
NCT03621280Phase 3Completed
- Sponsor
- Strongbridge Biopharma
- Start
- Jan 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of levoketoconazole in Cushing's syndrome and Cushing's disease (CD), sponsored by Strongbridge Biopharma. Primary endpoint: Proportions of Participants With Mean Urinary Free Cortisol (mUFC) Categorization Based on Upper Limit of Normal (ULN) up to 3 years. Started Jan 2019; status: completed.
02
Drugs
levoketoconazole
03
Conditions
Cushing's syndromeCushing's disease (CD)
Beyond the preview
Go deeper on NCT03621280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03621280.